Southern California Islet Cell Resources (SCI-ICR) Center

在之前的资助期间，南加州胰岛小区资源(SC-ICR)中心 已经成为ICR计划中最有成效的胰岛移植中心之一 同时还为全国范围内ICR批准的项目提供高质量的小岛。我们还有 在南加州组建了一个由几个移植中心组成的财团，并正在努力 对他们进行培训和鉴定，使其成为使用临床级胰岛的胰岛移植地点 由SC-ICR制作。在这些和其他方面，SC-ICR证明了它 发挥真正的胰岛细胞资源中心的作用。 在接下来的一段时间里，我们将把这一成功扩展到改善胰岛细胞分离， 表征和存储。在具体目标1中，我们计划扩大SC-ICR的能力 通过建造一个完全专用的设施，增加另一个胰岛隔离队，最多折叠三个，以及 增加器官采购活动。在具体目标2中，我们针对几个关键领域 以提高胰岛的恢复和效力。我们正在研究氧气补充在 胰岛分离过程中的特异点，促凋亡途径的抑制，以及 补充生长因子以最大限度地提高每个器官的胰岛产量。在特定目标中3 我们建立了一个基于最新技术的广泛的胰岛特征分析平台。 这些检测侧重于提供胰岛身份和纯度的有效表征， 胰岛功能定量分析及多中心的建立 研究确定与临床结果相关的分子。在具体目标4中，我们 通过开发胰岛存储和开发方法来解决胰岛短缺的问题 建立国家小岛储存库。我们的目光也超越了僵尸岛的孤立 以开发新的胰岛素产生细胞来源。 最后，我们认真对待ICR方案的目的是促进两国之间的合作 领先的胰岛隔离中心，并与其他人建立了多项合作努力 ICR计划的成员。作为这一努力的一部分，我们正在努力为许多 由SC-ICR创建的技术、协议、数据库和其他生物信息学资源 (具体目标5)。因此，SC-ICR计划被定位为在胰岛分离和 分销活动和提高小岛产量、质量和质量的技术开发 评估和临床应用。

In the previous funding period, the Southern California Islet Cell Resources (SC-ICR) Center has established itself as one of the most productive islet transplantation centers in ICR program while also providing high quality islets to ICR-approved projects nationwide. We have also assembled a consortium of several transplant centers in Southern California and are working to train and qualify them as islet transplantation sites which will use the clinical-grade islets produced by the SC-ICR. In these and other ways, the SC-ICR has demonstrated that it functions as a true islet cell resource center. In the upcoming period we will extend this success to improving islet cell isolation, characterization, and storage. In Specific Aim 1, we plan to expand the capacity of the SC-ICR up to three folds by constructing a fully dedicated facility, adding another islet isolation team, and increasing organ procurement activities. In Specific Aim 2, we are targeting a few crucial areas for improvement in islet recovery and potency. We are investigating oxygen supplementation at specific points in the islet isolation procedure, inhibition of pro-apoptotic pathways, and supplementation of growth factors to maximize the islet yield from every organ. In Specific Aim 3 we establish an extensive platform of islet characterization assays based on latest technologies. These assays focus on providing validated characterization of islet identity and purity, quantitative functional assays for determining islet potency, and establishment of a multicenter study to identify molecules that are associated with clinical outcome. In Specific Aim 4 we address the problem of islet shortage by development methods for islet storage and establishment of a national islet repository. We are also looking beyond cadaveric islet isolation to development of new sources of insulin-producing cells. Finally, we take seriously the purpose of the ICR program to foster cooperation between leading islet isolation centers and have established several collaborative efforts with other members of the ICR program. As part of this effort, we are working to provide access to the many techniques, protocols, databases, and other bioinformatics resources created by the SC-ICR (Specific Aim 5). Thus, the SC-ICR program is positioned to lead advances in islet isolation and distribution activities and the development of technologies for improving islet yield, quality, quality assessment, and clinical utilization.